deltatrials
Enrolling By Invitation PHASE1 INTERVENTIONAL 2-arm NCT07038447

A Study of KITE-363 in Participants With Refractory Autoimmune Diseases

A Phase 1 Open-label, Multiregional, Multicenter, Basket Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy in Participants With Refractory Autoimmune Diseases

Sponsor: Kite, A Gilead Company

Conditions Idiopathic Inflammatory Myopathy Lupus Nephritis Systemic Lupus Erythematosus Systemic Sclerosis
Interventions Cyclophosphamide Fludarabine KITE-363
Updated 4 times since 2025 Last updated: Jan 9, 2026 Started: Jul 2, 2025 Primary completion: Jul 31, 2029 Completion: Jul 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Idiopathic Inflammatory Myopathy and Lupus Nephritis and is currently ongoing. Kite, A Gilead Company leads this study, which shows 4 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshot~Aug 2025 – ~Jan 2026 · 5 months · monthly snapshotEnrolling By Invitation~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshot~Feb 2026 – present · 7 months · monthly snapshotEnrolling By Invitation

Change History

4 versions recorded

  1. Feb 2026 — Present [monthly]

    Enrolling By Invitation PHASE1

  2. Jan 2026 — Feb 2026 [monthly]

    Enrolling By Invitation PHASE1

  3. Aug 2025 — Jan 2026 [monthly]

    Enrolling By Invitation PHASE1

    Status: Not Yet Recruiting → Enrolling By Invitation

  4. Jul 2025 — Aug 2025 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Kite, A Gilead Company
Data source: Gilead Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations